BioMarin Pharmaceutical (BMRN) vs. Chiasma (CHMA) Head-To-Head Contrast

BioMarin Pharmaceutical (NASDAQ: BMRN) and Chiasma (NASDAQ:CHMA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

97.5% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 50.4% of Chiasma shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 3.8% of Chiasma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

BioMarin Pharmaceutical has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.


This table compares BioMarin Pharmaceutical and Chiasma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical -15.54% -5.77% -4.00%
Chiasma N/A -35.96% -31.97%

Analyst Ratings

This is a breakdown of recent recommendations for BioMarin Pharmaceutical and Chiasma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical 0 6 16 0 2.73
Chiasma 1 0 0 0 1.00

BioMarin Pharmaceutical currently has a consensus target price of $112.00, indicating a potential upside of 17.73%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Chiasma.

Earnings & Valuation

This table compares BioMarin Pharmaceutical and Chiasma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
BioMarin Pharmaceutical $1.20 billion 13.89 -$106.70 million ($1.09) -87.28
Chiasma N/A N/A -$29.42 million ($1.27) -2.09

Chiasma has higher revenue, but lower earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.


BioMarin Pharmaceutical beats Chiasma on 9 of the 12 factors compared between the two stocks.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

About Chiasma

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply